BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 27816821)

  • 1. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
    Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
    Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
    J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
    Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
    J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy.
    Zhang C; Shi G; Zhang J; Song H; Niu J; Shi S; Huang P; Wang Y; Wang W; Li C; Kong D
    J Control Release; 2017 Jun; 256():170-181. PubMed ID: 28414151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
    Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM
    Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components.
    Lin TJ; Lin HT; Chang WT; Mitapalli S P; Hsiao PW; Yin SY; Yang NS
    Mol Cancer; 2015 Sep; 14():174. PubMed ID: 26403780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
    Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
    Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polydopamine nanoparticles carrying tumor cell lysate as a potential vaccine for colorectal cancer immunotherapy.
    Wang X; Wang N; Yang Y; Wang X; Liang J; Tian X; Zhang H; Leng X
    Biomater Sci; 2019 Jun; 7(7):3062-3075. PubMed ID: 31140475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
    van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
    Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
    Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-Based Mucosal Vaccines Targeting Tumor-Associated Antigens to Human Dendritic Cells.
    Baleeiro RB; Schweinlin M; Rietscher R; Diedrich A; Czaplewska JA; Metzger M; Lehr CM; Scherlieb R; Hanefeld A; Gottschaldt M; Walden P
    J Biomed Nanotechnol; 2016 Jul; 12(7):1527-43. PubMed ID: 29337492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
    Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
    Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy.
    Ochyl LJ; Bazzill JD; Park C; Xu Y; Kuai R; Moon JJ
    Biomaterials; 2018 Nov; 182():157-166. PubMed ID: 30121425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.